Literature DB >> 30177019

Histologic Classification of IgA Nephropathy: Past, Present, and Future.

Maria F S Soares1, Ian S D Roberts2.   

Abstract

IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide. Since its description in 1968, a number of histologic descriptions and classification systems have emerged, the most recent of which is the Oxford Classification of IgAN. We present a historical panorama of histologic classifications of IgAN and discuss the most recent developments, updates, and future challenges of the Oxford Classification of IgAN.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  IGA nephropathy; classification; diagnosis; pathology

Mesh:

Year:  2018        PMID: 30177019     DOI: 10.1016/j.semnephrol.2018.05.017

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  4 in total

1.  Arteriolar hyalinosis and renal outcomes in patients with immunoglobulin A nephropathy.

Authors:  Yunzhu Shen; Tangli Xiao; ZhiKai Yu; Yinghui Huang; Ting He; Haiyang Li; Jun Zhang; Jiachuan Xiong; Jinghong Zhao
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

Review 2.  Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood.

Authors:  Antonio Mastrangelo; Jessica Serafinelli; Marisa Giani; Giovanni Montini
Journal:  Front Pediatr       Date:  2020-05-12       Impact factor: 3.418

Review 3.  Has The Time Arrived to Refine The Indications of Immunosuppressive Therapy and Prognosis in IgA Nephropathy?

Authors:  Bogdan Obrișcă; Ioanel Sinescu; Gener Ismail; Gabriel Mircescu
Journal:  J Clin Med       Date:  2019-10-02       Impact factor: 4.241

4.  Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria.

Authors:  Gaiqin Pei; Jiaxing Tan; Yi Tang; Li Tan; Zhengxia Zhong; Ling Zhou; Changyun Chen; Wei Qin
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.